Các bài viết có thể truy cập công khai - Eric JonaschTìm hiểu thêm
Không có ở bất kỳ nơi nào: 9
Đánh giá
Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations
GG Malouf, SM Ali, K Wang, S Balasubramanian, JS Ross, VA Miller, ...
European urology 70 (2), 348-357, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial
C Tang, P Msaouel, K Hara, H Choi, V Le, AY Shah, J Wang, E Jonasch, ...
The lancet oncology 22 (12), 1732-1739, 2021
Các cơ quan ủy nhiệm: US Department of Defense, US National Institutes of Health, Cancer …
Đánh giá
Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease
XM Keutgen, P Hammel, PL Choyke, SK Libutti, E Jonasch, E Kebebew
Nature reviews Clinical oncology 13 (9), 537-549, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial
E Jonasch, IE McCutcheon, DS Gombos, K Ahrar, ND Perrier, D Liu, ...
The Lancet Oncology 19 (10), 1351-1359, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Mammalian target of rapamycin (mTOR) inhibitor‐associated non‐infectious pneumonitis in patients with renal cell cancer: Predictors, management, and outcomes
BJ Atkinson, DH Cauley, C Ng, RE Millikan, L Xiao, P Corn, E Jonasch, ...
BJU international 113 (3), 376-382, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma
BI Rini, Y Tomita, B Melichar, T Ueda, V Grünwald, MN Fishman, ...
Clinical genitourinary cancer 14 (6), 499-503, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Phase II study of carfilzomib in patients with refractory renal cell carcinoma
E Hasanov, RSS Tidwell, P Fernandez, L Park, C McMichael, NM Tannir, ...
Clinical Genitourinary Cancer 17 (6), 451-456, 2019
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Chronic hepatitis C virus infection and genitourinary cancers: A case-control study
G Angelidakis, P Mahale, E Jonasch, Y Jiang, HA Torres
Seminars in oncology 47 (2-3), 165-167, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Conclusions: In two retrospective chart reviews EVE was associated with consistently reduced hazards of 2nd-line treatment failure in mRCC compared to TEM and TKIs.
MK WONG, E JONASCH, SK PAL, JE SIGNOROVITCH, PL LIN, Z LIU, ...
Các cơ quan ủy nhiệm: US National Institutes of Health
Có tại một số nơi: 156
Đánh giá
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Các cơ quan ủy nhiệm: Swiss National Science Foundation, US National Institutes of Health, US …
Đánh giá
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ...
Annals of Oncology 32 (5), 661-672, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health, Cancer Prevention Research Institute of …
Đánh giá
Renal cell carcinoma
E Jonasch, J Gao, WK Rathmell
Bmj 349, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ...
Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Belzutifan for renal cell carcinoma in von Hippel–Lindau disease
E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, VK Narayan, ...
New England Journal of Medicine 385 (22), 2036-2046, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health, UK Medical Research Council
Đánh giá
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
E Jonasch, CL Walker, WK Rathmell
Nature Reviews Nephrology 17 (4), 245-261, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L Zhou, XD Liu, M Sun, X Zhang, P German, S Bai, Z Ding, N Tannir, ...
Oncogene 35 (21), 2687-2697, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
The PI3K/AKT pathway and renal cell carcinoma
H Guo, P German, S Bai, S Barnes, W Guo, X Qi, H Lou, J Liang, ...
Journal of genetics and genomics 42 (7), 343-353, 2015
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Everolimus versus sunitinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial
NM Tannir, E Jonasch, L Albiges, E Altinmakas, CS Ng, SF Matin, X Wang, ...
European urology 69 (5), 866-874, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
BI Rini, B Melichar, T Ueda, V Grünwald, MN Fishman, JA Arranz, AH Bair, ...
The lancet oncology 14 (12), 1233-1242, 2013
Các cơ quan ủy nhiệm: US National Institutes of Health
Đánh giá
Dual chromatin and cytoskeletal remodeling by SETD2
IY Park, RT Powell, DN Tripathi, R Dere, TH Ho, TL Blasius, YC Chiang, ...
Cell 166 (4), 950-962, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health, V Foundation, USA
Chương trình máy tính sẽ tự động xác định thông tin xuất bản và thông tin về nhà tài trợ